CAMBRIDGE, Massachusetts, February 9, 2022– Takeda (TSE:4502/NYSE:TAK) today announced the U.S. Food and Drug Administration (FDA) approval of the Takhzyro® (lanadelumab-flyo) injection single-dose prefilled syringe (PFS) to…Original Article
Takeda Receives U.S. FDA Approval for Prefilled Syringe Presentation of Takhzyro (lanadelumab-flyo) for Use as a Preventive Treatment for Hereditary Angioedema Attacks
